Study Outlines Principles for Using CAR Immunotherapies to Treat Neurodegenerative Diseases

CAR therapies for neurodegeneration: A big challenge with increasingly plausible solutions

The application of CAR immunotherapies to neurodegenerative diseases is limited by major challenges due to the complex nature of these pathologies and the heterogeneity of harmful molecules to be treated. Nonetheless, and despite uncertainties, the initial findings are encouraging to continue advancing research, still in its very early stages.

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

Moving In Vivo: Next Steps For CAR T-Cell Therapy

There is no doubt that autologous chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of serious blood cancers. A significant proportion of advanced-stage blood cancer patients who failed to respond to previous therapies now go into remission with this treatment, with some remaining cancer-free in the long term. However, despite their success, these immunotherapies have significant disadvantages. Although CAR T-cell t…

Advancing CAR Therapies for Neurodegeneration: Overcoming Challenges with

A revolutionary frontier is emerging in the battle against neurodegenerative diseases, driven by the versatile and powerful approach of Chimeric Antigen Receptor (CAR) immunotherapies. Researchers at the Universitat Autònoma de Barcelona (UAB) have taken a critical step forward by defining the foundational principles that these therapies must embody to transition from conceptual frameworks to tangible clinical advancements. Their insights were r…

CAR Therapy Moves Beyond Cancer

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell platforms, including NK cells, γδ T cells, natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells, and double-negative T cells (DNT), regulatory T cells (Tregs), macrophages, dendritic cells, neutrophils, and stem-cell-based systems.